Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients.
Cholecystokinin (CCK) binding sites were assessed in post-mortem brain membrane preparations from controls and schizophrenic patients. 125I-BH CCK33 specific binding was reduced by 40% (p less than 0.02) in the hippocampus and by 20% (p less than 0.01) in the frontal cortex of schizophrenic patients compared with controls. There were no differences in 125I-BH CCK33 binding between the two groups in the amygdala, temporal cortex or caudate nucleus.
D000328:Adult; D000368:Aged; D000679:Amygdala / Q000378:metabolism; D001665:Binding Sites; D002421:Caudate Nucleus / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism*; D002766:Cholecystokinin / Q000378:metabolism*; D005260:Female; D006624:Hippocampus / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000378:metabolism*
D002766:Cholecystokinin